» Articles » PMID: 38854052

Limited Immunogenicity of an HLA-A*03:01-restricted Epitope of Erv-k-env in Non-hiv-1 Settings: Implications for Adoptive Cell Therapy in Cancer

Overview
Journal Res Sq
Date 2024 Jun 10
PMID 38854052
Authors
Affiliations
Soon will be listed here.
Abstract

Repetitive elements (REs) are often expressed at higher levels in tumor cells than normal cells, implicating these genomic regions as an untapped pool of tumor-associated antigens. In ovarian cancer (OC), protein from the RE ERV-K is frequently expressed by tumor cells. Here we determined whether the targeting of a previously identified immunogenic epitope in the envelope gene of ERV-K resulted in target antigen specificity in non-HIV-1 settings. We found that transducing healthy donor T cells with an ERV-K-Env-specific T cell receptor construct resulted in antigen specificity only when co-cultured with HLA-A*03:01 B lymphoblastoid cells. Furthermore, these transduced T cells were not specific for HLA-A*03:01 + OC cells nor for the cognate peptide in HLA-matched systems from multiple healthy donors. These data suggest that the ERV-K-Env epitope recognized by this T cell receptor is of low immunogenicity and has limited potential as a T cell target for OC.

References
1.
Desrichard A, Snyder A, Chan T . Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res. 2015; 22(4):807-12. DOI: 10.1158/1078-0432.CCR-14-3175. View

2.
Calarota S, Baldanti F . Enumeration and characterization of human memory T cells by enzyme-linked immunospot assays. Clin Dev Immunol. 2013; 2013:637649. PMC: 3844203. DOI: 10.1155/2013/637649. View

3.
Buscher K, Trefzer U, Hofmann M, Sterry W, Kurth R, Denner J . Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res. 2005; 65(10):4172-80. DOI: 10.1158/0008-5472.CAN-04-2983. View

4.
Zamarin D, Burger R, Sill M, Powell Jr D, Lankes H, Feldman M . Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. J Clin Oncol. 2020; 38(16):1814-1823. PMC: 7255977. DOI: 10.1200/JCO.19.02059. View

5.
Boegel S, Lower M, Bukur T, Sahin U, Castle J . A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. Oncoimmunology. 2015; 3(8):e954893. PMC: 4355981. DOI: 10.4161/21624011.2014.954893. View